Journal
VIROLOGY
Volume 490, Issue -, Pages 49-58Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.virol.2016.01.004
Keywords
MERS-CoV; Antibody therapy; Animal model, MERS; Respiratory syndrome; Human monoclonal antibody therapy
Categories
Funding
- NIAID Division of Intramural Research
- Battelle Memorial Institute
- US National Institute of Allergy and Infectious Diseases (NIAID) [HHSN272200700016I]
- National Cancer Institute, National Institutes of Health [HHSN261200800001E]
- NIAID [R01AI085524]
- Defense Advanced Research Projects Agency [W911NF-10-0226]
Ask authors/readers for more resources
Middle East Respiratory Syndrome Coronavirus (MERS-CoV) was identified in 2012 as the causative agent of a severe, lethal respiratory disease occurring across several countries in the Middle East. To date there have been over 1600 laboratory confirmed cases of MERS-CoV in 26 countries with a case fatality rate of 36%. Given the endemic region, it is possible that MERS-CoV could spread during the annual Hajj pilgrimage, necessitating countermeasure development. In this report, we describe the clinical and radiographic changes of rhesus monkeys following infection with 5 x 10(6) PFU MERS-CoV Jordan-n3/2012. Two groups of NHPs were treated with either a human anti-MERS monoclonal antibody 3B11-N or E410-N, an anti-HIV antibody. MERS-CoV Jordan-n3/2012 infection resulted in quantifiable changes by computed tomography, but limited other clinical signs of disease. 3B11-N treated subjects developed significantly reduced lung pathology when compared to infected, untreated subjects, indicating that this antibody may be a suitable MERS-CoV treatment. Published by Elsevier Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available